Principals
We are an interdisciplinary founder team with more than 10 years in diagnostic devices development, especially with non-invasive and saliva based technologies; a regulatory affairs expert with 30 years experience in Class III and Class II medical devices/biotechnology products, and a 24-year otolaryngological clinical practice and clinical trials. We have also built an impressive Medical Advisory board to help assist with our continued growth. The board includes members with clinical and research experience with more than 20 years in gastroesophageal reflux diseases, more than 30 years of industry experience in both the medical device and biopharmaceutical sectors, holding leadership positions at Medtronic, Johnson & Johnson (Acclarent), Intersect ENT, and others; more than 18-year Vice President and Head of National Medical Policy and Operations for Aetna Health Insurance & 12 years practicing emergency and general medicine, and 10 years of clinical research and clinical trials experts in salivary Biomarkers and cancers.
Stacey L. Silvers, MD CEO & FOUNDER
Private practicing Otolaryngologist 23 years in NY, NY. Owner of Madison ENT and Allergy Care. Extensive experience with LPR (Laryngopharyngeal reflux disease) and its affects on chronic upper respiratory disease and health. She has conducted at least 20 FDA trials including one specific to a new device for treatment of LPR. Dr. Silvers has 20 years experience conducting FDA trials with many journal publications. She has presented new device technology to the FDA for approval and has been a Touro College professor teaching otolaryngology for 19 years. Dr. Silvers is devoted to RJS Mediagnostix and its future potential, she will run the pilot trial and oversee the day to day research activities and development of this innovative technology. During the research trials she will continue practicing medicine 3 days a week in order to keep active in the medical community and continue to work with her piers to start implementing this new testing to help make it a standard of care while helping lower the cost on the healthcare system. Once FDA approved, she will devote her full time to bring this technology to market and support the company with development of further lateral flow strip and device development for other salivary diagnostic point of care tests. Contact Dr. Silvers at ssilvers@rjsmedx.com.
Balwant Rai, MD CTO & FoundeR
Rai Balwant is Founder of the Noninvasive Diagnostic Technology and Treatment Group (NDTT), International Scientific Foundation of Salivary Diagnosis and BR Start Up Village, Denmark. He is also the President and Founder of the Board of Research Institute of Health Education Research and Technology. He is visiting professor of more than 10 universities. He has served as a Scientific Advisor to five pharmaceutical companies. He is also founder of the BR formula and BR regression equation used in forensic technology. He has published different scientific articles in international and national journals in saliva biomarkers, systemic diseases, novel devices, novel formulations, dentistry and medicine etc. Dr Balwant holds 20 patents (USA, EU, Canada, Mexico and India) in areas of diagnostic and treatment technologies, drug formulation, saliva diagnostics, nano-drug formulations, medical devices etc. His discoveries include patented saliva technologies for Alzheimer's disease, Parkinson's disease, concussion and sleep disorders. He is also founder of translational medicine and science fellowship program and Saliva Diagnostics fellowship program. He is Editor-in-Chief of different international journals and expert reviewer of different space agencies and different funding agencies etc. He is expert reviewer for NRF, South Africa and NASA Postdoctoral Program. He has residency in emergency medicine, laboratory medicine and medical imaging. He got Bachelor of Dental Surgery and medicine from India, M.D. from Catholic University, Belgium and Certificate in medical imaging, Catholic University, Belgium. Contact Dr. Balwant at rbalwant@rjsmedx.com.
Jim Miller, COO and Head of Research & Development
Regulatory affairs professional with over 30 years experience in development of class II and III medical devices, in vitro diagnostics and biotechnology products. Expertise in development and implementation of global regulatory affairs, compliance to quality system management requirements and clinical research strategies. Recognized for his ability to identify risks and apply mitigations and expedite conflict resolutions to obtain timely product regulatory approval. Jim will devote full time to RJS on research and development to bring this technology in front of the FDA and eventually to market.
Contact Jim Miler at jmiller@rjsmedx.com.